explore -WSS

explore

author：comprehensive 2025-08-12 08:28:01 - browse：95297

Kevin Sayer, CEO of Dexcom Dexcom

For years, diabetes tech company Dexcom has been striving to get its continuous glucose monitors into the hands of type 2 diabetes patients. Last week at the American Diabetes Association’s conference, the company unveiled plans for software built entirely for these patients, including ones who don’t take insulin.

“We’ve been so focused on things that match the needs of somebody who manages diabetes every minute of every day, and insulin delivery,” Kevin Sayer, CEO of Dexcom, told STAT. “This new product is going to be designed to address the needs of somebody with diabetes who’s not doing that, who has type 2 diabetes and is on other drugs.”

Continuous glucose monitoring is already well-established among people with type 1 diabetes, who rely on constant insulin therapy. The technology, which helps patients noninvasively monitor their blood sugar levels and control their insulin pump in real time, has grown rapidly in use over the years, culminating in a $5 billion market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Thermo Fisher plant for manufacturing gene therapies to expand

WSS

FDA panel to weigh approval of NurOwn, controversial ALS drug

ProMED sees offers of support, but its future remains unclear

It's been 20 years since Dolly the sheep. Where's my clone?

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

Thermo Fisher plant for manufacturing gene therapies to expand

It's been 20 years since Dolly the sheep. Where's my clone?

hotspot

explore

explore

Psychedelics group wrestles with new pharma identity

Listen: Racing for gene therapy & a pioneering approval

Novavax promises a turnaround & Lilly roils the obesity market

CommonSpirit Health keeps growing, even as it loses money

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

CommonSpirit Health keeps growing, even as it loses money

The cancer drug shortage isn’t new — and neither are the solutions

Lasker Awards 2023: Winners in biomedical research

Virginia high school admissions case could be legal follow

Medical student insurance fails on mental health care coverage

knowledge

Living with Hashimoto's and celiac disease, and med school, too

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Lasker Awards 2023: Winners in biomedical research

Beware the threat of staffing cuts at the CDC

What Congress can do to address the rural doctor shortage

It's been 20 years since Dolly the sheep. Where's my clone?

focus

focus

entertainment

entertainment